# The Effect of Trimetazidine on Mitochondrial Function, Myocardial Performance, and Invasive Hemodynamics in Patients Diagnosed With Wild-Type Transthyretin Cardiac Amyloidosis

> **NCT05633563** · PHASE4 · COMPLETED · sponsor: **Steen Hvitfeldt Poulsen** · enrollment: 24 (actual)

## Conditions studied

- Transthyretin Amyloid Cardiopathy
- Mitochondrial Pathology

## Interventions

- **DRUG:** Trimetazidine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05633563
- **Lead sponsor:** Steen Hvitfeldt Poulsen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-01
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-06-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05633563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05633563, "The Effect of Trimetazidine on Mitochondrial Function, Myocardial Performance, and Invasive Hemodynamics in Patients Diagnosed With Wild-Type Transthyretin Cardiac Amyloidosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05633563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*